Crinetics [CRNX] vs Praxis Precision [PRAX] Detailed Stock Comparison

Crinetics Pharmaceuticals Inc.

NASDAQ
Loading...

Praxis Precision Medicines Inc.

NASDAQ
Loading...

TLDR: Quick Comparison Summary

Based on 17 vital metrics comparison: Crinetics Pharmaceuticals Inc. wins in 8 metrics, Praxis Precision Medicines Inc. wins in 6 metrics, with 0 ties. Crinetics Pharmaceuticals Inc. appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Crinetics Pharmaceuticals Inc. Praxis Precision Medicines Inc. Better
Price-to-Book Ratio 3.69 9.46 Crinetics Pharmaceuticals Inc.
Debt-to-Equity Ratio 4.89 0.01 Praxis Precision Medicines Inc.
PEG Ratio -9.40 -38.31 Crinetics Pharmaceuticals Inc.
EV/EBITDA -5.92 -26.32 Crinetics Pharmaceuticals Inc.
Profit Margin (TTM) 86.02% 0.00% Crinetics Pharmaceuticals Inc.
Operating Margin (TTM) -2,169.55% 0.00% Praxis Precision Medicines Inc.
Return on Equity -40.17% -45.83% Crinetics Pharmaceuticals Inc.
Return on Assets (TTM) -25.22% -28.69% Crinetics Pharmaceuticals Inc.
Free Cash Flow (TTM) $-383.68M $-249.12M Praxis Precision Medicines Inc.
1-Year Return 16.52% 807.83% Praxis Precision Medicines Inc.
Price-to-Sales Ratio (TTM) 521.49 N/A N/A
Enterprise Value $3.03B $8.58B Praxis Precision Medicines Inc.
EV/Revenue Ratio 394.23 N/A N/A
Revenue per Share (TTM) $0 N/A N/A
Earnings per Share (Diluted) $-4.93 $-13.48 Crinetics Pharmaceuticals Inc.
Beta (Stock Volatility) 0.31 2.97 Crinetics Pharmaceuticals Inc.
Short % of Float 17.21% 14.21% Praxis Precision Medicines Inc.

Crinetics Pharmaceuticals Inc. vs Praxis Precision Medicines Inc. Stock Performance Analysis

Loading Price Chart...

CRNX
PRAX

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Crinetics Pharmaceuticals Inc.1.47%-10.06%-19.78%-17.52%-29.57%-29.19%
Praxis Precision Medicines Inc.8.08%-21.90%-17.38%-12.35%49.84%-2.61%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Crinetics Pharmaceuticals Inc.16.52%61.52%109.86%54.57%54.57%54.57%
Praxis Precision Medicines Inc.807.83%2,210.03%21.08%-16.07%-16.07%-16.07%

Performance & Financial Health Analysis: Crinetics Pharmaceuticals Inc. vs Praxis Precision Medicines Inc.

MetricCRNXPRAX
Market Information
Market Cap i$4.01B$9.60B
Market Cap CategoryMid capMid cap
10 Day Avg. Volume i869,784391,453
90 Day Avg. Volume i1,130,331416,321
Last Close$33.09$278.93
52 Week Range$25.83 - $57.99$37.19 - $366.52
% from 52W High-42.94%-23.90%
All-Time High$62.53 (Nov 11, 2024)$914.27 (Jan 04, 2021)
% from All-Time High-47.08%-69.49%
Growth Metrics
Quarterly Revenue Growth42.08%N/A
Quarterly Earnings GrowthN/A-1.00%
Financial Health
Profit Margin (TTM) i0.86%0.00%
Operating Margin (TTM) i-21.70%0.00%
Return on Equity (TTM) i-0.40%-0.46%
Debt to Equity (MRQ) i4.890.01
Cash & Liquidity
Book Value per Share (MRQ)$10.38$34.85
Cash per Share (MRQ)$9.82$21.52
Operating Cash Flow (TTM) i$-377,921,984$-249,068,000
Levered Free Cash Flow (TTM) i$-206,911,632$-146,253,744
Dividends
Last 12-Month Dividend Yield iN/AN/A
Last 12-Month Dividend iN/AN/A

Valuation & Enterprise Metrics Analysis: Crinetics Pharmaceuticals Inc. vs Praxis Precision Medicines Inc.

MetricCRNX (Apr 26, 2026)PRAX (Apr 26, 2026)
Price Ratios
P/E Ratio (TTM) iN/AN/A
Forward P/E i-9.40-38.31
PEG Ratio i-9.40-38.31
Price to Sales (TTM) i521.49N/A
Price to Book (MRQ) i3.699.46
Market Capitalization
Market Capitalization i$4.01B$9.60B
Enterprise Value i$3.03B$8.58B
Enterprise Value Metrics
Enterprise to Revenue i394.23N/A
Enterprise to EBITDA i-5.92-26.32
Risk & Other Metrics
Beta i0.312.97
Book Value per Share (MRQ) i$10.38$34.85

Financial Statements Comparison: Crinetics Pharmaceuticals Inc. vs Praxis Precision Medicines Inc.

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricCRNX (2025)PRAX (2025)
Revenue/Sales i7.70M0
Cost of Goods Sold i1.08MN/A
COGS % of Revenue i14.0%-
Gross Profit i6.62MN/A
Gross Margin i86.0%-
Research & Development i332.06M267.12M
Operating Income (EBIT) i-516.77M-326.20M
Operating Margin i-6,714.8%-
EBITDA i-512.88M-326.06M
EBITDA Margin i-6,664.2%-
Pre-Tax Income i-465.14M-303.27M
Pre-Tax Income % of Revenue i-6,043.9%-
Income Tax i180,000N/A
Income Tax % of Revenue i2.3%-
Net Income (Profit) i-465.32M-303.27M
Profit Margin i-6,046.2%-

Balance Sheet & Liquidity Metrics

MetricCRNX (2025)PRAX (2025)
Cash & Equivalents i101.54M357.33M
Total Current Assets i1.05B610.91M
Total Current Assets % of Revenue i13,621.9%-
Total Current Liabilities i85.07M59.77M
Total Current Liabilities % of Revenue i1,105.4%-
Long-Term Debt i42.05M0
Long-Term Debt % of Revenue i546.4%-
Total Shareholders Equity i992.08M878.14M
Retained Earnings i-1.42B-1.14B
Retained Earnings % of Revenue i-18,417.7%-
Property, Plant & Equipment i50.45M415,000

Cash Flow Statement Comparison

MetricCRNX (2025)PRAX (2025)
Operating Cash Flow i-375.02M-257.32M
Operating Cash Flow % of Revenue i-4,872.9%-
Capital Expenditures i-5.76M-56,000
Free Cash Flow i-383.68M-249.12M
FCF Margin i-4,985.5%-
Debt Repayment iN/AN/A
Common Stock Repurchase i0N/A

Short Interest & Institutional Ownership Analysis

MetricCRNXPRAX
Shares Short i16.06M3.95M
Short Ratio i12.909.07
Short % of Float i17.21%14.21%
Shares Outstanding i95.58M25.20M
Float Shares i96.25M25.78M
% Held by Insiders i1.98%0.40%
% Held by Institutions i111.10%106.12%
% Held by Public i-13.08%-6.52%

Dividend Analysis & Yield Comparison: Crinetics Pharmaceuticals Inc. vs Praxis Precision Medicines Inc.

MetricCRNXPRAX
Last 12-Month Dividend iN/AN/A
Last 12-Month Dividend Yield iN/AN/A
3-Year Avg Annual Dividend iN/AN/A
3-Year Avg Dividend Yield iN/AN/A
3-Year Total Dividends iN/AN/A
Ex-Dividend DateN/AN/A